Caribou Biosciences Inc Total Liabilities

Latest as of June 2026: $44.67 Million USD

Caribou Biosciences Inc total liabilities. Based on the latest financial reports, Caribou Biosciences Inc (CRBU) has total liabilities worth $44.67 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Caribou Biosciences Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Caribou Biosciences Inc (2019–2025)

Total liabilities of Caribou Biosciences Inc from 2019 to 2025. This chart illustrates how Caribou Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Caribou Biosciences Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.

Caribou Biosciences Inc Competitors by Total Liabilities

The table below lists competitors of Caribou Biosciences Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Voksel Electric Tbk JK:VOKS	Indonesia	Rp1.46 Trillion
Hyperion DeFi, Inc. NASDAQ:HYPD	USA	$11.20 Million
Riverview Rubber Estates Bhd KLSE:2542	Malaysia	RM33.39 Million
Nuveen New York Select Tax-Free Income Portfolio NYSE:NXN	USA	$658.55K
Concorde International Group Ltd Class A Ordinary Shares NASDAQ:CIGL	USA	$7.57 Million
Avertronics TWO:3597	Taiwan	NT$1.06 Billion
Ledlink Optics TWO:5230	Taiwan	NT$1.02 Billion
DSK Co. Ltd KQ:109740	Korea	₩29.68 Billion

Liability Composition Analysis (2019–2025)

This chart breaks down Caribou Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Caribou Biosciences Inc.

Liquidity & Leverage Metrics

Caribou Biosciences Inc Total Liabilities Ratios Explained

Caribou Biosciences Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	6.49	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.46	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.31	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Caribou Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Caribou Biosciences Inc (2019–2025)

The table below shows the annual total liabilities of Caribou Biosciences Inc from 2019 to 2025.

Year	Total Liabilities	Change
2025-12-31	$53.19 Million	-11.88%
2024-12-31	$60.36 Million	-5.40%
2023-12-31	$63.81 Million	-12.46%
2022-12-31	$72.89 Million	+33.67%
2021-12-31	$54.53 Million	-8.33%
2020-12-31	$59.48 Million	+9.20%
2019-12-31	$54.47 Million	--

About Caribou Biosciences Inc

NASDAQ:CRBU USA Biotechnology

Market Cap

$47.64 Million

Market Cap Rank

#21905 Global

#4891 in USA

Share Price

$0.44

Change (1 day)

-3.27%

52-Week Range

$0.42 - $2.43

All Time High

$30.29